EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 158 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors MOST POPULAR For Esophageal Cancer, Immunotherapy Likely to Play Larger Role October 19, 2020 Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast September 21, 2021 Test Detects Early Signs of Remaining Cancer in Kids Treated for... December 8, 2021 First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma March 5, 2024 Load more HOT NEWS Man Offers Free Lawn Mowing Service To Elderly And Veterans Study Identifies Hundreds of Potential Targets for Cancer Drugs Why I Work to Bridge the Gap Between People With Cancer... Coping With Social Isolation as a Teen With Cancer
